Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
(Reuters) - Novo Nordisk, the world's largest insulin maker, has been reported to the police by Denmark's financial watchdog for not disclosing at once that its big new product hope Tresiba had been refused U.S. approval.
The Danish Financial Supervisory Authority (FSA) said the company should have issued a statement about the U.S. decision not to approve its new long-acting insulin on the evening of Friday, February 8, and not wait until Sunday, February 10, as it did.
The news that the Food and Drug Administration (FDA) had declined to approve Tresiba and a related combination drug called Ryzodeg was a major blow to Novo and confounded expectations of investors, who had expected a green light.
http://uk.reuters.com/article/2013/12/10/us-novo-police-idUKBRE9B907J20131210
The Danish Financial Supervisory Authority (FSA) said the company should have issued a statement about the U.S. decision not to approve its new long-acting insulin on the evening of Friday, February 8, and not wait until Sunday, February 10, as it did.
The news that the Food and Drug Administration (FDA) had declined to approve Tresiba and a related combination drug called Ryzodeg was a major blow to Novo and confounded expectations of investors, who had expected a green light.
http://uk.reuters.com/article/2013/12/10/us-novo-police-idUKBRE9B907J20131210